Effect of insulin-like growth factor binding proteins on the response of proximal tubular cells to insulin-like growth factor-I  by Yap, Jason et al.
Kidney International, Vol. 52 (1997), pp. 1216—1223
Effect of insulin-like growth factor binding proteins on the
response of proximal tubular cells to insulin-like growth factor-I
JASON YAP, TANNY TSAO, JANET FAWCETF, PAUL J. FIELDER, GILBERT A. KELLER, and RALPH RABKIN
Medicine Service Veterans Affairs Palo Alto Health Care System, Palo Alto; and Department of Stanford University School of Medicine,
Stanford; and Genentech Inc., South San Francisco, California, USA
Ell'ect of insulin-like growth factor binding proteins on the response of
proximal tubular cells to insulin-like growth factor-I. The insulin-like
growth factor binding proteins (IGFBP) are major modulators of insulin-
like growth factor-I (IGF-I) action, but relatively little is known about
their production by kidney tubular cells or about their modulating effects
on the action of IGF-I on these cells. In this study we demonstrated that
rabbit proximal tubular cells express the genes for IGFBP-2, -4 and -5 and
secrete 24 and 32 kDa size binding proteins. The rate of IGFBP
production by these cells was regulated by several growth factors including
hydrocortisone, which was potently stimulatory, and EGF, which was
inhibitory. The overall effect of these kidney cell-secreted IGFBPs was to
inhibit the mitogenic activity of IGF-I. Similarly, recombinant IGFBP-3,
the major circulating IGFBP that in kidney is produced close to the
proximal tubules, also inhibited IGF-L stimulated DNA synthesis in
cultured rabbit proximal tubular cells and in cultured opossum kidney
(OK) cells. IGFBP-3 also inhibited basal DNA synthesis in OK cells in the
absence of added IGF-I, suggesting that this IGFBP may have an IGF-I
independent action. These findings highlight the important effect that
IGFBPs have on the action of IGF-I on kidney cells and support the
notion that the changes in IGFBPs observed in various renal diseases may
contribute to the pathophysiology of these diseases.
Insulin-like growth factor-I (IGF-I) is a multifunctional growth
factor produced in a variety of tissues including kidney [1, 2]. Its
major renal actions include enhancement of tubular phosphate
transport, renal blood flow, glomerular filtration rate and organ
growth [2]. Indeed, IGF-I may participate in the induction of renal
hypertrophy in several pathological conditions including diabetes
mellitus, compensatory renal growth and hypokalemia [31. The
action of IGF-I is influenced by several IGF high-affinity binding
proteins (IGFBPs) that are present in the circulation and are also
produced locally throughout the body in a tissue specific pattern
[1, 4]. Six IGFBPs have been identified [4]. In the circulation only
ito 2% of the IGF-I is present in a freely bioavailable form [1, 5]
and the balance is complexed to IGFBPs including IGFBPs-I
through -4. Of these IGFBP-3 is by far the most abundant and it
accounts for> 90% of the complexed hormone in adult serum [4].
The overall effect of complex formation is a slowing of the passage
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of IGF-I into the tissues. In the tissues the IGFBPs originating
locally or from the circulation are usually inhibitory [6], but there
are reports that some EGFBPs may enhance IGF-I action [7—9].
This may arise through the trapping of IGF-I by cell associated
IGFBPs with facilitation of the interaction between IGF-I and its
receptor. Trapped IGF-I could also serve as a reservoir for the
sustained release of the growth factor. Furthermore, IGFBPs may
have cellular actions independent of IGF-I [1, 10, 11].
In kidney the genes for all six IGFBPs are detectable, though
IGFBP-6 is present in low abundance [12, 13]. There is marked
anatomical heterogeneity of expression of these genes in the
kidney that suggests that the IGFBPs may have diverse functions.
However, there is little information on the impact of tissue
TGFBPs whether derived locally or from the circulation [14], on
the renal actions of IGF-I [15, 16]. This may be of special
importance to our understanding of disease states, for the changes
in the IGFFBP profile that occur in a variety of kidney diseases
may contribute to the pathophysiology of the disease by modifying
the action of IGF-I [3, 17, 18].
In the present study we set out to characterize the IGFBPs
produced by proximal tubular cells, determine the influence of
growth factors on their production, and in turn discover the
impact of the secreted IGFBPs on the mitogenic action of IGF-I.
To this end rabbit proximal tubular cells were studied in primary
culture. In addition, we examined the effect of recombinant
IGFBP-3 on the action of IGF-I on these cells and on cultured
opossum kidney (OK) cells, a cell line that has retained features
of proximal tubular epithelium [19]. Insulin-like growth factor
binding protein-3 was studied since in vivo the proximal tubules
are likely exposed to tissue IGFBP-3 derived locally and from the
circulation. This 43 to 53 kDa glycosylated protein is the most
abundant circulating IGFBP and is also produced in close prox-
imity to the proximal tubules in the peritublar compartment [12]
METHODS
Materials
Culture media was obtained from Gibco Laboratories (Grand
Island, NY, USA); [3H]-thymidine (0.2Ci/mmol), from Amersham
Corp.; bovine serum albumin (BSA) from Armour Pharmaceuti-
cal Co. (Kankakee, IL, USA); and other chemicals, including
bovine insulin and hydrocortisone from Sigma Chemical Co. (St.
Louis, MO, USA). The following recombinant human proteins
were provided by Genentech, Inc. (South San Francisco, CA,
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USA): IGF-I, des [1—3IIGF-I, glycosylated IGFBP-3, transform-
ing growth factor-n (TGF-/3), hepatocyte growth factor (HGF)
and growth hormone (GH). Epidermal growth factor (EGF) was
purchased from Amgen Biologicals (Thousand Oaks, CA, USA).
Preparation of radiolabeled IGF-I
IGF-I was radiodinated by the chioramine T method as before
and separated from free iodide by fractionation through a cellu-
lose acetate column [15]. The specific activity of the '251-IGF-I
was —300 to 400 iCi/jLg.
Cell cultures
Primary cultures of rabbit proximal tubular epithelial cells were
isolated and cultured as previously described [19]. For these
studies, monolayers were grown to confluency in one-half Dulbec-
co's modified Eagle's medium and one-half Ham's F-12 medium
(DMEM/F12; 17.5 m glucose) containing insulin (5 /LgIml),
hydrocortisone (50 nM) and transferrin (5 jtg/ml). Prior to study,
the monolayers were deprived of insulin and hydrocortisone for
48 hours. At the time of the experiments this medium was
refreshed with medium of the same composition containing 0.1%
bovine serum albumin (BSA). In experiments examining the
effects of growth factors or hydrocortisone, the monolayers were
incubated for a further 24 hours with or without these additions
present.
Opossum kidney (OK) cells from passages 40 to 50 were plated
on 11.3 mm plastic tissue culture wells (— 0.5 x 106 cells/well) in
DMEM/F-12 containing 10% (vol/vol) newborn calf serum, pen-
icillin (120 U/ml), and streptomycin (72 j.gIml) [15] and main-
tained at 37°C under an atmosphere of 5% C02-95% air. After
reaching confluency, the medium was replaced with serum free
medium of the same composition as before. Twenty-four hours
later, at the time of the experiments, the serum free medium was
refreshed with medium of the same composition containing 0.1%
BSA and iO— M EGF. EGF was included since in preliminary
experiments the presence of EGF enhanced IGF-I stimulated
DNA synthesis.
Cell number
Cells were washed with calcium and magnesium free phosphate
buffered saline, trypsinized, harvested and counted in a Coulter
counter (Coulter Electronics, Inc., Hialeah, FL, USA).
[3H1 -thymidine incorporation
Relative rates of DNA synthesis were determined from the
incorporation of [1H-thymidine into tichioroacetic acid (TCA)
insoluble material. Monolayers were incubated with 0.1 jiCi
[3H]-thymidine per ml for four hours at 37°C and then washed
with cold isotonic buffer and exposed to 10% TCA for 15 minutes.
TCA insoluble material was solubilized in 0.1% SDS with 0.1 N
NaOH and counted.
Charcoal adsorption assay
This was performed according to Concover et al [20]. In brief,
conditioned medium was collected from confluent monolayers.
Aliquots, 5 and 10 pi. were then incubated with 1251-IGF (1 X iO
cpm) in 0.5 ml PBS with 0.5% BSA for 18 hours at 4°C. After
incubation, I ml of 0.5% activated charcoal in PBS with 0.5% BSA
and 0.2 mg/mi protamine sulfate was added and the mixture kept
at 4°C for 45 minutes. Tubes were centrifuged at 3000 rpm for 30
minutes and the supernatant was separated from the charcoal
precipitate. Radioactivity in the supernatant, which contained
radioligand bound to binding proteins and the pellet, which
contained free 1251-IGF-l bound to charcoal, were counted in a
gamma-counter. Unconditioned medium to which 1251-IGF-I was
added was assayed simultaneously to correct for the nonspecific
appearance of free 1251-IGF-l in the supernatant.
Western ligand blot
To measure secreted IGFBPs, 48-hour conditioned media was
concentrated tenfold by centrifugation in Centricon-lO concentra-
tors (Amicon Inc., Beverly, MA, USA) and then analyzed accord-
ing to Hossensloop et ai [211. In brief an aliquot of the concen-
trate was dissolved in Laemmli's sample buffer, heated to 95°C for
five minutes and electrophoresed in a 12% SDS-polyacrylamide
gel. The separated proteins were electroblotted onto nitrocellu-
lose filters. These were blocked with BSA and Tween-20 and
probed with 1251-IGF-I (2 X 106 cpm) overnight at 4°C. The filter
was washed with Tris-buffered saline, air-dried and exposed to
Kodak XAR X-ray film for two to four days. The signal was
measured by densitometry (Gel Scan XL; Pharmacia LKB, Alam-
eda, CA, USA). It should be recognized that this is not a truly
quantitative assay because of variations in the transfer of the
IGFBPs to the nitrocellulose.
Northern blot analysis
For each analysis total mRNA was extracted from three or
more confluent monolayers of rabbit proximal tubular cells grown
in 10 cm diameter culture wells. This was achieved by the single
step method of Chomcznyski and Sacchi [22], using acid guani-
dinium thiocyanate-phenol chloroform extraction and the RNA
was quantitated by absorbance at 260 nm. For Northern analysis
of IGFBP mRNA levels, 12 g of total RNA was fractionated on
a 0.8% denatured agarose gel and the ethidium bromide stained-
RNA photographed under UV light. RNA was transferred to a
nitrocellulose membrane overnight and hybridized with [32P]d-
CTP labeled rat IGFBP-1, -2, -3, -4, and -5 eDNA probes as
previously described. To control for loading the filter was also
probed with radiolabeled human GAPDH eDNA [18].
Densitometric analysis
Radioactive and chemiluminescent signals captured on X-ray
films were quantitated by laser densitometry (GelscanXL; Phar-
macia LKB, Alameda, CA, USA).
Statistics
The results are expressed as the mean SEM. For comparisons
between two groups the data were analyzed with Student's t-test,
and a P value of < 0.05 was taken as significant. When three or
more (up to 5) groups were compared an analysis of variance was
used. If the F ratio was significant this was followed by Student's
t-test with Bonferronis adjustment for multiple comparison, and a
P value of < 0.01 was taken as significant [23].
RESULTS
Cultured primary rabbit proximal tubular cells
IGFBP genes are expressed by rabbit proximal tubular cells.
Messenger RNA extracted from cultured rabbit proximal tubular
cells and subjected to Northern analysis with rat IGFBP-1 to -5
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Table 1. Effect of growth factors and hydrocortisone on IGFBP mRNA levels in cultured rabbit proximal tubular cells
eDNA probes gave positive signals for IGFBP-2, -4 and -5only.
The effect of a variety of growth factors and hydrocortisone on the
expression of these mRNAs are summarized in Table 1 and an
example of a Northern blot analysis is shown in Figure 1.
Incubation with TGF—p, EGF and HGF, growth factors expressed
in kidney, decreased the IGFBP-2 and -4 mRNA levels signifi-
cantly while hydrocortisone increased the IGFBP-4 mRNA level
fourfold. IGFBP-5 mRNA levels were depressed significantly by
HGF and hydrocortisone. GAPDH mRNA levels were not af-
fected by any of the treatments.
Western ligand blot of IGFBPs secreted into the culture medium.
When culture medium conditioned for 48 hours was analyzed by
Western ligand blotting with 1251-IGF-I, two distinct bands of
IGF-I binding activity were detected (Fig. 2). These were —24 and
32 kDa in size and are most consistent in size with IGFBP-4 (24
kDa) and IGFBP-2 or -5 (——32 kDa). Similar size proteins are
present in rabbit serum [24].
Regulation of IGFBP secretion by growth ftwtors. Net TGFBP
secretion into the culture medium over 24 hours was quantitated
by a charcoal adsorption assay with '251-IGF-1 as the ligand. The
effects of GH, TGFJ3, EGF, HGF, hydrocortisone and insulin are
shown in Figure 3. TGF/3 and EGF each produced a modest, but
significant depression of IGFBP secretion (13 and 34%, respec-
tively). In contrast, GH stimulated a small (15%), but significant
increase in IGFBP secretion while hydrocortisone increased se-
cretion by 125% (P < 0.01); insulin had no effect. IGF-I was not
examined as it interferes with the charcoal assay.
IGF-I stimulates [3H]-thymidine incorporation and cell prolifer-
ation. In these experiments confluent cultured proximal tubular
cells were exposed to IGF-I or insulin, iO to 10 ' M, in serum
free medium for 24 hours to study DNA synthesis and 48 hours to
study cell proliferation. As depicted in Figure 4, IGF-1 stimulated
DNA synthesis and cell proliferation more effectively than insulin.
At IGF-I concentrations of 10 8 M or above, [3H]thymidine
incorporation increased significantly to values two- to threefold
greater than that seen in untreated control cells. A similar
response was seen with insulin at concentrations an order of
magnitude higher, i0 to 106 M. The IGF-I induced prolifera-
tive response mirrored DNA synthesis. IGF-I at concentrations of
l0 M or above stimulated a significant increase in cell number
Treatment
EGF HGF HydrocortisoneGH TGF-13
(50 nm) (4 nM) (10 nM) (10 nM) (1.4 jM)
IGFBP-2 193 42.7 64 12.5" 19 1.2" 35 4.0" 110 12.0
IGFBP-4 134 + 15.2 73 4.5" 23 53b 48 10.7" 394 124.8
IGFBP-5 144 29.5 71 11.5 117 14.5 65 11.Oa 25 160b
IGFBP mRNA levels were detected by Northern blot analysis and corrected for the corresponding GAPDH mRNA level. Results, mean SEM, are
from 3 to 6 separate experiments and are expressed as a percentage of the corresponding controls. Exposure to treatment was for 24 hours.
P < 0.05, "P < 0.01 versus control values
cP
— BP4
— GAPDH Fig. 1. Northern blot analysis of IGFBP-4 and
GAPDH mRNA levels in cultured proximal
tubular cells. Cells were incubated in the
presence or abscence of the indicated growth
factors for 24 hours at the concentrations listed
in Table 1. The autoradiographs are from a
single gel.
— 32 kDa
— 24 kDa
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Fig. 2. Western ligand blot of IGFBPs secreted by cultured rabbit
proximal tubular cells. The autoradiogram was obtained with 48-hour
conditioned culture medium; '251-IGF-I was used as the ligand.
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while insulin was only effective at 106 M. This proliferative
response to insulin is consistent with insulin cross-reacting with
and stimulating the IGF-I receptor.
Secreted IGFBPs inhibit IGF-I stimulated DNA synthesis. To
evaluate the effect of IGFBPs secreted by the rabbit kidney cells
on the action of IGF-I, we compared the dose response to IGF-I
in conditioned medium with that of des(1-3)IGF-I, a truncated
analog that binds to the IGF-I receptor with the same affinity as
the full length molecule [18], but binds poorly to IGFBPs [25].In
competitive binding experiments, we confirmed that this later
property also holds true for rabbit kidney cell IGFBPs. These
experiments (data not shown) revealed that the affinity of rabbit
kidney cell IGFBPs for des(1-3)IGF-I was reduced by more than
an order of magnitude compared to JGF-1. The half maximal
concentration of cold IGF-I or des(1-3)IGF-I that displaced 50%
of the tracer 1251-IGF-I bound to the kidney cell IGFBPs, a
measure of relative affinity, averaged 1.6 X 10b0 M for 1GF-I and
6 X iO M for des(1-3)IGF-I, respectively. Next we incubated
proximal tubular cell monolayers with 48-hour conditioned se-
rum-free medium containing increasing concentrations of IGF-I
or des(1-3)IGF-I and measured [3H]-thymidine incorporation. As
shown in Figure 5 at concentrations below 10—8 M, des(1-3)IGF-I
stimulated [3H]-thymidine incorporation to a significantly greater
extent than equimolar concentrations of IGF-I. Indeed, at 10b0
M IGF-I had no effect on 3H]-thymidine incorporation, while
des(i-3)JGF-I stimulated incorporation by 80% above the contol
value. This indicates that IGFBPs secreted by cultured rabbit
proximal tubular cells have a net inhibitory effect on IGF-I
stimulated DNA synthesis.
Recombinant IGFBP-3 inhibits IGF-I stimulated DNA synthesis
and proliferation. In these experiments [3H]-thymidine incorpora-
tion was measured after exposing rabbit proximal tubular cells to
1O M IGF-I for 24 hours in the presence of an equimolar
concentration of recombinant glycosylated human IGFBP-3 [26—
28] or vehicle (control). Monolayers were placed in fresh medium
containing IGFBP-3 and two hours later IGF-I was added;
IGFBP-3 was present throughout the subsequent incubation. As
shown in Table 2, IGFBP-3 inhibited IGF-1 stimulated [3H]-
thymidine incorporation significntly (P < 0.01). In other mono-
layers the cell number was measured after 48 hours of exposure
to IGF-I. As occurred with DNA synthesis, IGF-I stimulated
cell proliferation was inhibited when IGFBP-3 was present
Fig. 3. Effect of growth factors on net IGFBP production by rabbit
proximal tubular cells. Cells were incubated in the presence or absence
(controls) of growth factors for 24 hours. The following concentrations of
growth factors were added: GH 50 flM, TGF 4 nm, EGF 10 nm, HGF 10
nm and hydrocortisone 1.4 /LM. Conditioned medium was assayed by
means of the charcoal binding assay with 1251-IGF-I as the ligand. The
results are the mean SEM of 5 to 11 seperate experiments and are
expressed as the net percentage change in the treatment groups compared
to untreated controls. < 005 **< 0.01
(P < 0.05). Recombinant IGFBP-3 added to monolayers in the
absence of IGF-1 had no effect on DNA synthesis or cell
proliferation.
Cultured opossum kidney cells
IGF-I stimulated DNA synthesis and this was inhibited by free but
not cell associated IGFBP-3. Addition of 108 M IGF-I to conflu-
ent OK cell monolayers incubated in serum free culture medium
stimulated [3H]-thymidine by 26% (P < 0.01) compared to vehicle
treated controls. This is shown in Figure 6, which also shows the
effect of recombinant IGFBP-3 on basal and IGF-I stimulated
DNA synthesis. When OK cells were incubated with IGFBP-3
alone basal [3H]thymidine incorporation decreased significantly
by 29% (Fig. 6A). When cells were coincubated with IGF-I (10
nM) and increasing concentrations of IGFBP-3, growth factor
stimulated 3H1-thymidine incorporation was completely inhibited
at an IGFBP-3 concentration of 50 flM or above (Fig. 6B).
Since it is conceivable that OK cells may produce IGF-I, we
considered the possibility that the IGFBP-3 induced attenuation
of basal DNA synthesis might reflect the inhibition of endogenous
IGF-I. To test this concept, control monolayers incubated in
serum free medium were exposed to a neutralizing IGF-I antibody
(Upstate Biotechnology Inc., Lake Placid, NY, USA). At an
antibody concentration that completely blocks the stimulation of
DNA synthesis by 10—8 M IGF-I in OK cells there was a
statistically insignificant decrease in DNA synthesis averaging
10%. This argues against significant OK cell IGF-I production and
suggests that IGFBP-3 inhibits DNA synthesis through an IGF-I
independent action.
it has been shown that prolonged incubation of cultured
fibroblasts with IGFBP-3 can enhance their responsiveness to
IGF-I [7, 8]. This has been attributed to an increase in cell surface
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Fig. 4. Effect of IGF-I and insulin on [3H] thymidine incorporation (A)
and cell proliferation (B). Cultured rabbit proximal tubule cells were
incubated in serum free medium containing l0 M IGF-1 or insulin for 24
hours for measurement of [3Hj-thymidine incorporation (N = 3) and 48
hours for measurement of cell number (N = 8 separate experiments).
Symbols are (E, 01) IGF-J; (,•) insulin. P < 0.05, < 0.01 compared
to untreated controls.
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Fig. 5. Effect of IGF-I (•) and des(1-3)IGF-I (0) on [3H1-thymidine
—6 incorporation in cultured rabbit proximal tubular cells in the presence of
endogenous IGFBPs. Confluent rabbit proximal tubular cell monolayers
were incubated for 24 hours in 48-hour conditioned medium containing
increasing concentrations of IGF-I or des(1-3)IGF-I. *p < 0.05, P <
0.01 compared to controls (N = 4 separate experiments).
pared to vehicle incubated controls (10.8 0.3 vs. 9.5 0.4%!
monolayer, respectively, P < 0.01). To differentiate between
increased binding to IGF-I receptors or cell associated IGFBP-3,
*
displacement by iO M cold insulin was examined. Insulin at high
concentrations competes with IGF-I for the IGF-I receptor but
not for any binding proteins. In the presence of iO M cold
insulin, the residual radioactivity associated with IGFBP-3 pre-
treated cells was significantly greater than the radioactivity asso-
ciated with the contol cells (1.88 0.13 vs. 0.66 0.03%,
respectively, P < 0.001). Note that the difference in residual cell
associated radioactivity (1.22%) between the two groups was
comparable to the difference in total cell associated 1251-IGF-I
(1.3%). This indicates that the increase in 1251-IGF-l binding to
IGFBP-3 pretreated cells reflects sequestration of 1251-IGF-I by
cell associated IGFBP-3. However, unlike fibroblasts [7], the
IGFBP-3 mediated increase in OK cell associated IGF-I did not
enhance IGF-I stimulated DNA synthesis. In cells preincubated
with IGFBP-3 or vehicle for 72 hours [3H]thymidine incorpora-
tion averaged 2739 811 versus 2532 847 dpm!well, respec-
tively. In cells preincubated with IGFBP-3 or vehicle for 24 hours
[3H]-thymidine incorporation averaged 2190 298 versus 2024
196 dpm!well, respectively.
DISCUSSION
This study demonstrates that rabbit proximal tubular cells
grown in primary culture secrete IGFBPs that inhibit the mito-
genie action of IGF-I. Northern blot analysis showed that these
cells express IGFBP-2, -4 and -5 mRNAs and Western ligand blot
analysis of culture medium showed that they secrete IGFBPs of
molecular weights -=28 and 32 kDa. Similarly sized IGFBPs are
present in rabbit serum [24]. The regulation of IGFBP secretion
was quantified with a charcoal adsorption assay and we found that
TGFI3 and EGF, growth factors produced within the kidney,
reduced secretion modestly; growth hormone produced a minor
increase, while hydrocortisone stimulated secretion twofold. As
reported with IGFBPs from other animal species [25], the affinity
—10 —9 —8 —7 —6
Ligand concentration, log M
associated IGFBP-3 with increased trapping of IGF-I and expo-
sure to the IGF-I receptor. The following experiment tested
whether cell associated IGFBP-3, as opposed to free IGFBP-3 in
the experiments above, increases the association of IGF-I with
kidney cells and thereby enhances its action. OK cells were
preincubated with 108 M IGFBP-3 for 24 or 72 hours, the
medium was replaced with fresh IGFBP-3 free medium contain-
ing 1251-IGF-I (2 x 10— 10 M). As shown in Figure 7, preincubation
with IGFBP-3 for 72 hours produced a small but significant
increase in the total amount of cell associated [125I]IGF-I corn-
** ** **
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Table 2. Effect of IGFBP-3 on IGF-1 stimulated DNA synthesis and cell proliferation in rabbit proximal tubular cells
1221
Control IGFBP-3 IGF-1 IGF-1 + IGFBP-3
[3H]-thymidine incorporation 7.96 1.10 7.18 0.59 25.01 3.28" 17.92 310b
dpn, X103
Cell number X1O5 11.52 1.18 11.72 1.13 12.76 1.41° 11.95 1.51
DNA synthesis measured from incorporation of [3H]-thymidine after 24 hours exposure to test substance. Cell proliferation was measured after 48
hours. IGF-1 and IGFBP-3 were present at 10 M.
aP < 0.05, b P < 0.01 vs. all other groups
o i 1050100 0 1 1050100
IGFBP-3 concentration, nM
Fig. 6. Effect of the presence of IGFBP-3 in the culture medium on (A)
basal and (B) IGF-I stimulated [3H1-thymidine incorporation in OK
cells. Increasing concentrations of IGFBP-3 were added to confluent OK
cells incubated in serum free medium two hours before the addition of
vehicle (A) or 10 nM IGF-I (B). 3Hj-thymidine incorporation was
measured 24 hours later. *p < oo5, ap < 0.01 compared to respective
IGFBP-3 free controls (N = 4 separate experiments).
of these secreted IGFBPs for IGF-I was considerably greater than
for the truncated analog, des(1-3)IGF-I. In the presence of rabbit
cell IGFBPs, IGF-I stimulated the synthesis of DNA less effec-
tively than des(1-3)IGF-I. This is consistent with a reduction in
IGF-I availability due to sequestration by the secreted IGFBPs.
Next we examined the effect of IGFBP-3 on the action of IGF-I
since in vivo it is likely that the proximal tubules are exposed to
IGFBP-3 derived from the circulation and also to IGFBP-3
produced locally in the cortical peritubular compartment [12, 13].
We found that when rabbit proximal tubular cells were coincu-
bated with IGF-I and recombinant IGFBP-3, IGF-I-stimulated
DNA synthesis and cell proliferation were inhibited. Similarly,
IGFBP-3 inhibited DNA synthesis in cultured OK cells. These
findings are consistent with studies conducted with cultured
human mesangial cells [16] and cells derived from other tissues [9,
10, 26]. It is likely that inhibition is a consequence of IGF-1-
IGFBP-3 complex formation that limits the bioavailability of
IGF-I. Indeed, IGFBP-3 in solution exhibits a significantly greater
affinity for IGF-I than the IGF-T receptor [1]. Furthermore, in an
earlier study with OK cells we showed directly that IGFBP-3
inhibits IGF-I receptor binding and receptor mediated internal-
ization significantly [15].
In addition to inhibiting IGF-I action by reducing its bioavail-
ability, IGFBP-3 may have a direct IGF-I independent inhibitory
action. This has been described with IGFBP-3 transfected fibro-
blasts [11] and with a cultured breast cancer cell line [10], and may
possibly he mediated through IGFBP-3 specific receptors [27]. In
0
Fig. 7. Effect of preincubating cultured OK cells with IGFBP-3 for 72
hours for the cellular association of 1251—IGF-I. Monolayers were incu-
bated with IGFBP-3 (LI) or vehicle ( for 72 hours, washed twice and
then incubated in fresh IGFBP-3 free medium containing '251-IGF-I (2 ><
i0' M) with or without iO M insulin for 60 minutes at 37°C.
Radioactivity displaced by insulin is taken to reflect binding to receptors.
The difference in cell associated radioactivity between the two groups is
taken to reflect '251GF-I bound to cell associated IGFBP-3 (N = 5
experiments/group). < 0.01.
the present study we did find evidence that indicates that IG-
FBP-3 may have an IGF-I independent action on cultured OK
cells, but not rabbit tubular cells. Exposure of OK cells to
IGFBP-3 in the absence of exogenous IGF-I inhibited DNA
synthesis significantly by 30%. This was not mediated through the
inhibition of any IGF-I that might be produced by OK cells, for
the inhibitory effect of IGFBP-3 could not be reproduced with an
excess of IGF-1 specific blocking antibody. A potential mechanism
for the IGF-I independent action is suggested from a recent study
from this laboratory, which demonstrated that IGFBP-3 targets to
the nucleus of OK cells [28]. It is conceivable that the IGFBP-3
arriving in the nucleus directly inhibited DNA synthesis at this
site.
Adding to the complexity of the action of IGFBP-3 are reports
that IGFBP-3 may actually enhance the action of IGF-1 in
cultured cells such as fibroblasts and osteoblasts [7—9, 30]. In some
studies the enhancing effect was only observed when cells were
preincubated for 24 to 48 hours with IGFBP-3 and then, after
removing the protein from the incubation medium, the cells were
exposed to IGF-I [8, 9, 29]. This enhancing effect was thought to
be mediated through an increase in cell associated TGFBP-3 that
trapped and presented IGF-I to its receptors. In the present study
when OK cells were preincubated with IGFBP-3 for periods up to
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72 hours, cell associated IGFBP-3 increased significantly. How-
ever, unlike the studies described above, when the cells were
subsequently treated with IGF-I there was no enhancement or
inhibition of IGF-I action.
The situation in vivo is of course considerably more complicated
than in cell culture. Also, responses observed in vitro, especially in
cell lines, may be acquired under cell culture conditions. Accord-
ingly, despite the novel information derived from cells in culture,
caution must be exercised when extrapolating these data to the
situation in vivo. For example, while the immediate effect of
IGFBPs secreted by cultured proximal tubular cells are inhibitory,
it is conceivable that in vivo sequestration of IGF-I by IGFBPs
within the kidney could result in an elevation of local IGF-I levels
[31. In turn, the slow and sustained release of free IGF-I from this
pool, especially when IGF-I production is reduced, could increase
the interaction of IGF-I with the IGF-I receptor and thus
facilitate IGF-I activity [1, 31]. Such a process has been postulated
to occur in diabetes and in K depletion [3, 32]. Early in both these
conditions, kidney IGF-I levels increase even though in diabetes
the mRNA levels are unchanged, while in K depletion the levels
are actually reduced. The increase in IGF-I has been attributed in
part to elevated local IGFBP levels and may contribute to the
renal hypertrophy that occurs in diabetes and in K depletion [3,
321. From all this, it is apparent that our understanding of the
action of the IGFBPs in the kidney is very inadquate. Nevertheless
it seems reasonable to propose that the IGFBPs play a role in the
pathophysiology of certain renal diseases by altering the local
IGF-I levels and the interaction of IGF-I with its receptor.
In summary, we have shown that cultured rabbit proximal
tubular cells produce IGFBPs and that their rate of production is
inhibited by several growth factors, especially EGF, and stimu-
lated by others, especially hydrocortisone. These endogenous
IGFBPs have a net inhibitory effect on IGF-I stimulated DNA
synthesis. Similarly, the recombinant form of glycosylated IG-
FBP-3, the major circulating IGF binding protein, which in kidney
is produced in cells close to the proximal tubule, also inhibits
IGF-I stimulated DNA synthesis in cultured rabbit and OK cells.
Furthermore, it appears that in OK cells IGFBP-3 may have an
IGF-l-independent inhibitory action. Since in a variety of kidney
disease states there are marked changes in the circulating and
local kidney IGFBP profile, it may well be that these changes
contribute to the pathophysiologic process by influencing the
action of IGF-I and perhaps also through an IGF-1 independent
action. Unravelling the contribution of the various components of
the IGF-I—IGFBP system remains an important challenge.
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